Patents by Inventor Ursula-Henrike Wienhues-Thelen

Ursula-Henrike Wienhues-Thelen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210239712
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of FGFBP-1 in a sample from the subject, and comparing the amount of FGFBP-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of FGFBP-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: August 5, 2021
    Inventors: Peter Kastner, Andre Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Manuel Dietrich, Ulrich Schotten
  • Publication number: 20210215716
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.
    Type: Application
    Filed: February 22, 2021
    Publication date: July 15, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Peter Kastner, Manuel Dietrich, André Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Ulrich Schotten
  • Patent number: 11047866
    Abstract: Presented is a method for diagnosing and/or grading diastolic dysfunction or at least one structural or functional abnormality associated with diastolic dysfunction. The method involves measuring the level of IGFBP7 (Insulin like growth factor binding protein 7) and, optionally, the level of at least one further marker in a patient suffering from heart failure, and comparing the level to a reference level. Further envisaged is a method of monitoring diastolic function in a patient suffering from heart failure. Also described are kits and devices adapted to carry out the method.
    Type: Grant
    Filed: May 23, 2019
    Date of Patent: June 29, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Johann Karl, Ursula-Henrike Wienhues-Thelen, Dirk Block, Christian Zaugg, Hans-Peter Brunner, James Januzzi, Andre Ziegler, Julian Braz, Thomas Dieterle, Edelgard Kaiser
  • Publication number: 20210190801
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP 10 in a sample from the subject, and comparing the amount of BMP 10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP 10-type peptide in a sample from a subject.
    Type: Application
    Filed: February 17, 2021
    Publication date: June 24, 2021
    Inventors: Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Manuel Dietrich, Andre Ziegler, Ulrich Schotten
  • Publication number: 20210181211
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of TFPI-2 in a sample from the subject, and comparing the amount of TFPI-2 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for assessing anticoagulation therapy and to methods for predicting the risk of stroke of a subject. Said methods are based on the determination of the amount of TFPI-2 in a sample from the subject.
    Type: Application
    Filed: February 16, 2021
    Publication date: June 17, 2021
    Inventors: Peter Kastner, Andre Ziegler, Ursula-Henrike Wienhues-Thelen, Vinzent Rolny, Manuel Dietrich, Ulrich Schotten
  • Publication number: 20210172962
    Abstract: The present invention relates to a method for assessing the risk of stroke in a subject, said method comprising the steps of determining the amount of CES-2 in a sample from the subject, and comparing the amount of CES-2 to a reference amount, whereby the risk of stroke is to be assessed. Moreover, the present invention relates to a method for assessing the efficacy of an anticoagulation therapy and a method for identifying a subject being eligible to the administration of at least one anticoagulation medicament or being eligible for increasing the dosage of at least one anticoagulation medicament.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 10, 2021
    Inventors: Manuel Dietrich, Peter Kastner, Vinzent Rolny, Ulrich Schotten, Ursula-Henrike Wienhues-Thelen, Andre Ziegler
  • Publication number: 20210164969
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Application
    Filed: January 29, 2021
    Publication date: June 3, 2021
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Heudig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20210156875
    Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 27, 2021
    Applicants: Roche Diagnostics Operations, Inc., Universitaet Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Johann Karl, Peter Kastner, Roberto Latini, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Andre Ziegler, Manuel Dietrich, Jennifer Meessen, Ulrich Schotten
  • Publication number: 20210140971
    Abstract: The present invention relates to a method for assessing whether a pregnant subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not, said method comprising the steps of determining the amount of the biomarker IGFBP-7 (Insulin-like Growth Factor Binding Protein 7) in a sample from the subject, and comparing the determined amount of the biomarker to a reference. Further, the present invention relates to the in vitro use of the biomarker IGFBP-7, or of at least one detection agent which specifically binds to IGFBP-7 in a sample of a pregnant subject for assessing whether said subject is at risk of developing preeclampsia or a preeclampsia-related condition, or not. Also encompassed by the present invention is a device adapted to carry out the method of the present invention.
    Type: Application
    Filed: January 19, 2021
    Publication date: May 13, 2021
    Inventors: Martin Hund, Johann Karl, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10996229
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 4, 2021
    Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of Toronto
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10942175
    Abstract: Methods and systems for diagnosing functional and/or structural abnormalities of the heart preceding heart failure, and for predicting the risk of developing heart failure, in a subject comprising measuring a cardiac troponin in a sample and comparing the measurement to a reference value. Other markers, including GDF15 and IGFBP7 are also measured in some embodiments.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: March 9, 2021
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Dirk Block, Hendrik Huedig, Sabine Vogel-Ziebolz, Christine Boehm, Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20200371114
    Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.
    Type: Application
    Filed: December 19, 2019
    Publication date: November 26, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Publication number: 20200300869
    Abstract: The present disclosure demonstrates a method for predicting the risk of stroke of a subject and a method for improving the prediction accuracy of a clinical stroke risk score. The methods are based on the determination of the amount of Angiopoietin-2 (Ang-2) and/or the amount of Insulin-like growth factor-binding protein 7 (IGFBP7) in a sample from a subject. Moreover, disclose is the use of i) the biomarker Ang-2 and/or the biomarker IGFBP7, and/or ii) at least one detection agent that specifically binds to Ang-2 and/or at least one detection agent that specifically binds to IGFBP7 in a sample from a subject for predicting the risk of stroke of said subject.
    Type: Application
    Filed: June 12, 2020
    Publication date: September 24, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Ursula-Henrike Wienhues-Thelen, Johann Karl, Peter Kastner, Vinzent Rolny, Andre Ziegler, David Conen
  • Publication number: 20200271670
    Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for pikej3optimizing B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
    Type: Application
    Filed: May 7, 2020
    Publication date: August 27, 2020
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
  • Patent number: 10684291
    Abstract: The present description relates to a method for identifying a patient who is eligible for an intensification of heart failure therapy. Furthermore, the description relates to a method for optimizing B type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. The methods are based on the measurement of the level of at least one marker in a sample from a patient who has heart failure and who receives B-type natriuretic peptide (BNP) and/or N-terminal pro B-type natriuretic peptide (NT-proBNP)-type peptide guided heart failure therapy. Further described are kits and devices adapted to carry out the described method.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 16, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Dirk Block, Hans-Peter Brunner, Ursula-Henrike Wienhues-Thelen, Christian Zaugg, Thomas Dieterle, Cheryl Mitchell, Johan Ubby, Sandra Sanders-van Wijk
  • Publication number: 20200116708
    Abstract: Disclosed is a method for diagnosing paroxysmal atrial fibrillation in a subject, involving: determining the amount of FABP-3 (Fatty acid binding protein 3) in a sample from a subject suspected to suffer from paroxysmal atrial fibrillation, and comparing the determined amount to a reference amount. The method may further involve the determination of a BNP-type peptide. Also disclosed is a device adapted to carry out the method.
    Type: Application
    Filed: December 12, 2019
    Publication date: April 16, 2020
    Applicants: Roche Diagnostics Operations, Inc., Maastricht University Medical Center
    Inventors: Johann Karl, Peter Kastner, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen, Manuel Dietrich, Andre Ziegler, Ulrich Schotten
  • Publication number: 20200064359
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 27, 2020
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Patent number: 10557858
    Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: February 11, 2020
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Roberto Latini, Serge Masson, Dirk Block, Christian Zaugg, Thomas Dieterle, Edelgard Kaiser, Johann Karl, Vinzent Rolny, Ursula-Henrike Wienhues-Thelen
  • Patent number: 10488422
    Abstract: Disclosed is a method for assessing heart failure in vitro including the steps of measuring in a sample the concentration of the marker IGFBP-7, of optionally measuring in the sample the concentration of one or more other marker(s) of heart failure, and of assessing heart failure by comparing the concentration determined in for IGFBP-7 and the concentration(s) determined for the optionally one or more other marker to the concentration of this marker or these markers as established in a reference population. Also disclosed are the use of IGFBP-7 as a marker protein in the assessment of heart failure, a marker combination comprising IGFBP-7 and a kit for measuring IGFBP-7.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: November 26, 2019
    Assignees: Roche Diagnostics Operations, Inc., The Governing Council of the University of Toronto
    Inventors: Ursula-Henrike Wienhues-Thelen, Georg Hess, Hendrik Huedig, Herbert von der Eltz, Andrew Emili, Anthony Gramolini, Peter Liu, David MacLennan, Vincent Fong, Ruth Isserlin, Thomas Kislinger, Dirk Block
  • Publication number: 20190353666
    Abstract: The present disclosure relates to a method for predicting the risk of recurrence of Atrial Fibrillation in a subject based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. The present disclosure also contemplates a method of diagnosing Atrial Fibrillation in a subject suspected to suffer from Atrial Fibrillation based on determining the amount of the biomarker Angiopoietin-2 (Ang-2) and optionally of at least one further biomarker in a sample from the subject. Further envisaged are devices adapted to carry out the method of the present disclosure.
    Type: Application
    Filed: December 12, 2018
    Publication date: November 21, 2019
    Applicant: Roche Diagnostics Operations, Inc.
    Inventors: Herbert Andres, Dirk Block, Johann Karl, Peter Kastner, Ursula-Henrike Wienhues-Thelen, Roberto Latini, Serge Masson, Andre Ziegler, Edelgard Kaiser, Stefan Palme, Markus Thomas, Simona Barlera